Koch Disruptive Technologies Invests in Sight Diagnostics Alongside OurCrowd in $71 Million Series D

Koch Disruptive Technologies has announced an investment in Sight Diagnostics alongside global crowdfunding platform OurCrowd. Sight Diagnostics is a long time portfolio company of OurCrowd. The Series D funding raised a solid $71 million. Total funding now tops $124 million. A valuation of the Medtech firm was not provided.

Sight is a company that has developed the first FDA-cleared fingerstick Complete Blood Count (CBC) analyzer. The company is competing in the space that Theranos attempted to enter but actually providing a service that works. The tech is being used at Sheba Hospital to minimize risks during the Covid crisis.